BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Pharma (ASND)Ascendis PharmaCompany update

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis - Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept.

Related news

ASNDAscendis Pharma2026-08-25 20:01 EST

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

ASNDAscendis Pharma2026-06-08 20:59 EST

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis Announces Planned $400 Million Share Repurchase Program

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

ASNDAscendis Pharma2026-09-09 20:01 EST

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

ASNDAscendis Pharma2026-09-08 20:01 EST

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ASNDAscendis Pharma2026-09-07 11:00 EST

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Stock data

Close
239.04 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States